Treatment of asthma with anti-immunoglobulin E monoclonal antibody.
Clinical experience with anti-immunoglobulin E monoclonal antibody therapy (i.e., omalizumab) for asthma is maturing. Now several years after U.S. Food and Drug Administration approval and release, more studies of the clinical efficacy and safety of omalizumab have been published. We are gaining a better understanding of those patients with asthma who are likely to benefit from the therapy. The large majority of patients with asthma who meet the U.S. Food and Drug Administration-approved criteria for omalizumab therapy have severe persistent asthma. Additionally, in patients with severe disease, several predictive markers of clinical improvement with omalizumab therapy have been identified recently. There is good reason to have increasing comfort with omalizumab therapeutic trials, especially in those with severe asthma.
Liu
Andrew H
AH
Division of Pediatric Allergy and Clinical Immunology, National Jewish Medical & Research Center, University of Colorado School of Medicine, Denver, Colorado 80206, USA. liua@njc.org
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000187:drug effects* / Q000276:immunology; D008297:Male; D020714:Maximum Tolerated Dose; D000069444:Omalizumab; D011379:Prognosis; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E